⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402160 | 0.81 | — | — | |
| SCHEMBL4951742 | 0.79 | — | — | |
| SCHEMBL9628883 | 0.75 | — | — | |
| SCHEMBL4039889 | 0.75 | — | — | |
| SCHEMBL4818791 | 0.74 | — | — | |
| SCHEMBL4818775 | 0.74 | — | — | |
| SCHEMBL19305259 | 0.74 | — | — | |
| SCHEMBL8391276 | 0.71 | — | — | |
| SCHEMBL1601866 | 0.71 | — | — | |
| SCHEMBL2255605 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| CN-106188175-B | Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds | 轩竹(北京)医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3150617-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | CIPLA USA INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2217610-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-6420372-B1 | TROPICAL MALARIAL ANTIPROTOZOAN | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| WO-2001042194-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
| EP-1076057-A1 | FEBRIFUGINE AND ISOFEBRIFUGINE AND PROCESSES FOR THE PREPARATION OF BOTH | Japan Science and Technology Corporation (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-6084082-A | SOLID PHASE SYNTHESIS BY ATTACHING BETA-LACTAM HAVING NUCLEOBASE TO SOLID SUPPORT, DEPROTECTING HYDROXY GROUP, REACTING FREE HYDROXYL GROUP WITH BETA-LACTAMTIDE HAVING ACTIVATED PHOSPHITE GROUP, AND OXIDIZING | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5866691-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5554746-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5332807-A | Process of producing 8A- and 9A-azalide antibiotics | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| WO-1994015617-A1 | 8A-AZA AND 9A-AZA MACROLIDE ANTIBIOTICS, AND A PROCESS FOR PRODUCING SAME AND METHODS OF USE | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |